Sector News

Merck lays out up to $5.8B for half of Eisai's Lenvima

March 8, 2018
Life sciences

Less than eight months after nabbing a 50% share of hot AstraZeneca drug Lynparza, Merck is back with another partnership—this time on Eisai’s Lenvima.

Wednesday, the two companies said they’d inked a collaboration pact on the tyrosine kinase inhibitor that could bring Eisai up to $5.76 billion. In return, Merck will reap half of Lenvima’s sales, both as a monotherapy and in tandem with its own cancer drug, Keytruda.

Of course, how much Eisai eventually walks away with will depend on how Lenvima fares, sales-wise. Merck will hand over $300 million up front and up to $650 million more for certain rights, along with $450 million in R&D reimbursement. $385 million more will hang on whether the partners can hit certain clinical and regulatory targets. But the rest—up to $3.97 billion—will depend on whether the partners hit their sales marks.

Merck was already plenty familiar with the potential of Lenvima before striking the deal. In January, the Lenvima-Keytruda combo snagged the FDA’s “breakthrough” designation in kidney cancer based on positive phase 1b/2 data that dropped last year.

Now, though, that combo will head into a host of new clinical trials, with the new partners plotting 11 potential indications across endometrial cancer, non-small cell lung cancer, hepatocellular carcinoma, head and neck cancer, bladder cancer and melanoma.

Eisai entered the collaboration “aiming to maximize the potential of Lenvima and expedite the creation of innovative treatments in this age of ‘Cancer Evolution,’” Eisai CEO Haruo Naito said in a statement.

For Merck, it’s the second blockbuster cancer deal its pulled off since July, when it teamed up with PARP drugmaker AstraZeneca on an $8.5 billion collaboration for Lynparza. And as Evercore ISI analyst Umer Raffat pointed out in a Wednesday note to clients, “there is an interesting dynamic playing out among the two lead players in immuno-oncology.”

Bristol-Myers Squibb “has continued to progress the most IO-IO combos into phase 3,” he noted, and meanwhile, “Merck has been extremely focused on flawless trial execution with IO-chemo and has added two important small molecule combinations to its portfolio via partnerships.”

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

March 19, 2023

Ferring Pharmaceuticals’ 1st in class C.diff Treatment, Rebyota, experiences a positive early launch ahead of potential competition

Life sciences

With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.

March 19, 2023

UCB enters drug discovery collaboration with Aitia

Life sciences

Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.

March 19, 2023

Novo, Medtronic add $25M in fuel to FIRE1 and its heart failure monitoring device

Life sciences

Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.

How can we help you?

We're easy to reach